PMID- 30554486
OWN - NLM
STAT- MEDLINE
DCOM- 20190121
LR  - 20200225
IS  - 1976-2437 (Electronic)
IS  - 0513-5796 (Print)
IS  - 0513-5796 (Linking)
VI  - 60
IP  - 1
DP  - 2019 Jan
TI  - Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in Korea: A Narrative 
      Review.
PG  - 10-21
LID - 10.3349/ymj.2019.60.1.10 [doi]
AB  - Antineutrophil cytoplasmic antibody-associated vasculitis (AAV) is a group of 
      systemic necrotising vasculitides, which often involve small vessels, and which 
      lead to few or no immune deposits in affected organs. According to clinical 
      manifestations and pathological features, AAV is classified into three variants: 
      microscopic polyangiitis, granulomatosis with polyangiitis (GPA), and 
      eosinophilic GPA. The American College of Rheumatology 1990 criteria contributed 
      to the classification of AAV, although currently the algorithm suggested by the 
      European Medicines Agency in 2007 and the Chapel Hill Consensus Conference 
      Nomenclature of Vasculitides proposed in 2012 have encouraged physicians to 
      classify AAV patients properly. So far, there have been noticeable advancements 
      in studies on the pathophysiology of AAV and the classification criteria for AAV 
      in Western countries. However, studies analysing clinical features of Korean 
      patients with AAV have only been conducted and reported since 2000. One year-, 5 
      year-, and 10 year-cumulative patient survival rates are reported as 96.1, 94.8, 
      and 92.8%. Furthermore, initial vasculitis activity, prognostic factor score, age 
      and specific organ-involvement have been found to be associated with either 
      all-cause mortality or poor disease course. The rate of serious infection is 
      28.6%, and 1 year-, 5 year- and 10 year-cumulative hospitalised infection free 
      survival rates range from 85.1% to 72.7%. The overall standardised incidence 
      ratio of cancer in AAV patients was deemed 1.43 compared to the general Korean 
      population.
CI  - (c) Copyright: Yonsei University College of Medicine 2019.
FAU - Choi, Chan Bum
AU  - Choi CB
AUID- ORCID: 0000-0002-4691-5455
AD  - Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, 
      Seoul, Korea.
FAU - Park, Yong Beom
AU  - Park YB
AUID- ORCID: 0000-0003-4695-8620
AD  - Division of Rheumatology, Department of Internal Medicine, and Institute for 
      Immunology and Immunological Diseases, Yonsei University College of Medicine, 
      Seoul, Korea.
FAU - Lee, Sang Won
AU  - Lee SW
AUID- ORCID: 0000-0002-8038-3341
AD  - Division of Rheumatology, Department of Internal Medicine, and Institute for 
      Immunology and Immunological Diseases, Yonsei University College of Medicine, 
      Seoul, Korea. sangwonlee@yuhs.ac.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Korea (South)
TA  - Yonsei Med J
JT  - Yonsei medical journal
JID - 0414003
RN  - 0 (Antibodies, Antineutrophil Cytoplasmic)
SB  - IM
MH  - Anti-Neutrophil Cytoplasmic Antibody-Associated 
      Vasculitis/classification/*epidemiology/etiology/mortality
MH  - Antibodies, Antineutrophil Cytoplasmic/adverse effects
MH  - Humans
MH  - Incidence
MH  - Prognosis
MH  - Republic of Korea/epidemiology
PMC - PMC6298898
OTO - NOTNLM
OT  - Antineutrophil cytoplasmic antibody
OT  - Korea
OT  - vasculitis
COIS- The authors have no potential conflicts of interest to disclose.
EDAT- 2018/12/17 06:00
MHDA- 2019/01/22 06:00
PMCR- 2019/01/01
CRDT- 2018/12/17 06:00
PHST- 2018/05/23 00:00 [received]
PHST- 2018/12/17 06:00 [entrez]
PHST- 2018/12/17 06:00 [pubmed]
PHST- 2019/01/22 06:00 [medline]
PHST- 2019/01/01 00:00 [pmc-release]
AID - 60.10 [pii]
AID - 10.3349/ymj.2019.60.1.10 [doi]
PST - ppublish
SO  - Yonsei Med J. 2019 Jan;60(1):10-21. doi: 10.3349/ymj.2019.60.1.10.